GREENVILLE, S.C.--June 2, 2022--(BUSINESS WIRE)--Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be…

KIYATEC one of four private companies among forty-three featured at the two-day event GREENVILLE, S.C.--(BUSINESS WIRE)--KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced that CEO…